The role of long chain omega-3 polyunsaturated fatty acids on weight loss and maintenance
Not Applicable
Recruiting
- Conditions
- ObesityDiet and Nutrition - Obesity
- Registration Number
- ACTRN12609000204246
- Lead Sponsor
- The University of Newcastle
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Body Mass Index (BMI) between 30 and 40
Can consume fish
Can swalllow capsules
Exclusion Criteria
BMI >40
Diabetic
Already consuming fish oil capsules or more than 2 oily fish meals/week
Has inflammatory condition
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of % change in total body fat from baseline between groups using bioelectrical impedance[At baseline, at 4 weeks and at 14 weeks, all within the treatment period];Comparison of % change in fat free mass from baseline between groups using biolectrical impedance assessment[At baseline, at 4 weeks and at 14 weeks, all within the treatment period];Comparison of % change in weight from baseline between groups using a calibrated balance beam scale to measure weight[At baseline, at 4 weeks and at 14 weeks, all within the treatment period]
- Secondary Outcome Measures
Name Time Method Comparison of changes in inflammatory biomarkers from baseline between groups using commercially available Enzyme Linked ImmunoSorbent Assays (ELISAs), namely, Leptin, Adiponectin, Interleukin-6 (IL-6), Tumour Necrosis Factor alpha (TNFa) and Leukotriene B4 (LTB4)[At baseline, at 4 weeks and at 14 weeks, all within the treatment period];Comparison of changes in blood glucose from baseline between groups. Fasting blood glucose will be analysed by Hunter Area Pathology Services[At baseline, at 4 weeks and at 14 weeks, all within the treatment period];Comparison of changes in all plasma lipids from baseline between groups. Plasma fatty acid profiles will be determined using Gas Chromatography analysis.[At baseline, at 4 weeks and at 14 weeks, all within the treatment period]
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link omega-3 PUFAs to adipose tissue regulation in obesity?
How does omega-3 supplementation compare to standard-of-care weight management interventions in obese populations?
Are there specific biomarkers that predict individual response to long chain omega-3 PUFA supplementation for weight loss?
What adverse events are associated with high-dose omega-3 PUFA supplementation in obese individuals?
What combination therapies with omega-3 PUFAs show enhanced efficacy for weight maintenance in clinical studies?